[go: up one dir, main page]

WO2018155435A1 - Préparation granulaire - Google Patents

Préparation granulaire Download PDF

Info

Publication number
WO2018155435A1
WO2018155435A1 PCT/JP2018/005990 JP2018005990W WO2018155435A1 WO 2018155435 A1 WO2018155435 A1 WO 2018155435A1 JP 2018005990 W JP2018005990 W JP 2018005990W WO 2018155435 A1 WO2018155435 A1 WO 2018155435A1
Authority
WO
WIPO (PCT)
Prior art keywords
granule
valine
leucine
granule preparation
gelling agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/005990
Other languages
English (en)
Japanese (ja)
Inventor
泰士 谷川
千里 牧野
信豪 二宮
純 小坂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EA Pharma Co Ltd
Original Assignee
EA Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EA Pharma Co Ltd filed Critical EA Pharma Co Ltd
Priority to CN201880003639.1A priority Critical patent/CN109789120A/zh
Priority to PH1/2019/500671A priority patent/PH12019500671B1/en
Priority to JP2019501340A priority patent/JP7080215B2/ja
Priority to KR1020197007437A priority patent/KR102555664B1/ko
Publication of WO2018155435A1 publication Critical patent/WO2018155435A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention relates to a granule preparation. Specifically, the present invention relates to a granule preparation containing isoleucine, leucine and valine.
  • Rebact registered trademark, hereinafter the same
  • Rebact-blended granule contains 4g of active ingredient in 1 packet (4.15g), and is used to improve hypoalbuminemia in patients with decompensated cirrhosis who exhibit hypoalbuminemia despite adequate food intake (Non-Patent Document 1).
  • the rebact-blended granule is a granule preparation containing a large amount of amino acid components, further improvement in the ingestion feeling such as bitterness derived from amino acids and the mouthfeel of the granules is required.
  • the problem to be solved by the present invention is to provide a granule preparation containing isoleucine, leucine and valine with improved dosing feeling.
  • the present invention is as follows.
  • a granule preparation comprising isoleucine, leucine and valine as active ingredients, comprising a gelling agent.
  • the granule preparation according to any one of (1) to (5), comprising isoleucine / leucine / valine 1 / 1.9 to 2.2 / 1.1 to 1.3 in a weight ratio.
  • a method for producing a granule preparation comprising isoleucine, leucine and valine as active ingredients, A production method of adding a gelling agent to granules containing isoleucine, leucine and valine. (10) The production method according to (9), wherein the gelling agent is added as a powder.
  • Example 1 The result in the elution test of the granule formulation of Example 1 is shown.
  • the result in the elution test of the granule formulation of the comparative example 1 is shown.
  • the granule preparation of the present invention contains isoleucine, leucine and valine as active ingredients and contains a gelling agent.
  • isoleucine, leucine and valine used as active ingredients are amino acids known as branched chain amino acids.
  • D-form and L-form may be used, respectively, a mixture of D-form and L-form in any mixing ratio may be used, and DL-form may be used.
  • Each of isoleucine, leucine and valine may be a chemically synthesized product or a fermented product.
  • Japanese Pharmacopoeia (483, 1711 to 1712, pages 1248, respectively)
  • those satisfying the standards described as L-isoleucine, L-leucine and L-valine are preferably used.
  • containing isoleucine, leucine and valine as active ingredients means that, when the granule preparation of the present invention is used as a pharmaceutical, it contains isoleucine, leucine and valine as ingredients that exhibit efficacy effects. means.
  • the efficacy effect of pharmaceuticals containing isoleucine, leucine and valine as active ingredients in Japan, it is the efficacy effect of rebact-containing granule, which is a commercial product.
  • the improvement of hypoalbuminemia in patients with decompensated cirrhosis presenting is known, but the efficacy effect of the granule preparation containing isoleucine, leucine and valine as active ingredients of the present invention is not limited to this efficacy effect.
  • the granule preparation of the present invention can be used as a pharmaceutical granule preparation by containing isoleucine, leucine and valine as active ingredients.
  • the content of isoleucine, leucine and valine is set as appropriate, but it is preferably 80% or more, more preferably 90% or more as the lower limit of the content as mass% with respect to the total amount of the granule preparation. And more preferably 95% or more.
  • the upper limit of the content of isoleucine, leucine and valine is not particularly limited, but the content of isoleucine, leucine and valine is preferably less than 100%, more preferably 99% or less, and 98% Or less, more preferably 97% or less.
  • the content of isoleucine, leucine and valine may be in a range in which respective values described as preferable values as the upper limit value and the lower limit value are combined.
  • the granule preparation of the present invention contains a gelling agent.
  • the gelling agent means a preparation additive that is a base material that gels by containing water.
  • the gelling agent is not particularly limited, and examples thereof include hypromellose, methylcellulose, hydroxypropylcellulose, carboxyvinyl polymer, sodium alginate, carrageenan, xanthan gum, tamarind gum, pectin, locust bean gum, gellan gum, agar and polyethylene oxide. It is done. From the viewpoints of gelation ability and gelation speed, carboxyvinyl polymer and polyethylene oxide are preferable, and polyethylene oxide is more preferable.
  • a gelatinizer may be used by 1 type and may be used as a 2 or more types of mixture.
  • the average molecular weight of the gelling agent is appropriately set depending on the type of gelling agent from the viewpoint of indexes such as gelling ability and gelling speed.
  • the gelling ability can be confirmed, for example, by observing the appearance when the gelling agent is dissolved in water at high and low concentrations.
  • the gelation speed can be confirmed by adding and dissolving the gelling agent in water and stirring the mixture and observing the state of gelation over time.
  • Examples of the measurement concentration for gelation ability include high concentration (10 w / v%) and low concentration (1 w / v%), and examples of the measurement concentration for gelation rate include 10 w / v%.
  • the lower limit of the average molecular weight preferably has an average molecular weight of 150,000 or more, more preferably has an average molecular weight of 500,000 or more, and more preferably has an average molecular weight of 1,000,000 or more. More preferably, it has an average molecular weight of 2 million or more.
  • the upper limit of the average molecular weight of polyethylene oxide is not particularly limited, but the average molecular weight of polyethylene oxide is preferably 10 million or less, and more preferably 5 million or less.
  • the average molecular weight of the polyethylene oxide may be a range in which respective values described as preferable values as the upper limit value and the lower limit value are combined.
  • the average molecular weight of the gelling agent may be a value displayed on the product, but can be measured as the viscosity average molecular weight by measuring the viscosity of the gelling agent solution.
  • the gelling agent contained in the granule preparation of the present invention is preferably present by adding powder.
  • the powder addition of the gelling agent is performed on elementary granules containing isoleucine, leucine and valine.
  • the gelling agent is present on the surface of the granule as a granule preparation.
  • the granule preparation of the present invention is a so-called coated granule (coated granule).
  • coated granule coated granule
  • the elementary granules containing isoleucine, leucine and valine are coated with a coating solution.
  • the gelling agent is contained in the coating liquid.
  • the presence of the gelling agent added in powder form in the granule preparation is not particularly limited, but for example, it is confirmed by evaluating the gelation ability of the powder obtained by separation by sieving etc. be able to. Moreover, it can also confirm that the gelatinizer exists by adding powder by spectroscopic image observation.
  • the content of the gelling agent is appropriately set depending on the type of the gelling agent, but from the viewpoint of gelling ability and gelling speed, it is preferably 0.01 to 5% as mass% with respect to the total amount of the granule preparation. 0.05 to 2% is more preferable, and 0.05 to 1% is still more preferable. The content of the gelling agent may be 0.1% or more within the above range.
  • the granule preparation of the present invention can be produced by adding a gelling agent to granules containing isoleucine, leucine and valine produced by a conventionally known method.
  • isoleucine, leucine and valine may be mixed and ground with solid raw material amino acids such as isoleucine, leucine and valine to adjust the particle size by the method described in Japanese Patent No. 3228288.
  • solid raw material amino acids such as isoleucine, leucine and valine to adjust the particle size by the method described in Japanese Patent No. 3228288.
  • For the mixing and pulverization either a method of pre-mixing isoleucine, leucine and valine and then pulverizing or a method of pulverizing while mixing isoleucine, leucine and valine can be used.
  • the mixing of the solid raw material amino acid is not particularly limited, but, for example, stirring mixing by rotating a container rotating mixer such as a container mixer, an air stirring mixer such as a fluidized bed mixer, a stirring blade and a stirring ribbon
  • a feeder type mixer installed at a raw material supply port such as a machine, a line mixer for mixing in a powder transportation line, or a pulverizer can be used.
  • the solid raw material amino acid pulverization is not particularly limited.
  • impact type (high-speed rotation type) pulverizer such as hammer mill and pin mill
  • tumbler type (medium type) pulverizer such as ball mill
  • fluid type such as jet mill (jet mill) Airflow type
  • pulverizer can be used.
  • granules containing isoleucine, leucine and valine of the present invention it is not particularly limited.
  • a high-speed stirring granulator, a fluidized bed granulator, a planetary mixer, a dry compaction granulator, a crush granulation A machine, an extrusion granulator, a rolling granulator, a spray drying granulator or a coating granulator can be used. It is preferable to produce granules using a high-speed stirring granulator or an extrusion granulator.
  • extrusion granulator Although it does not specifically limit as an extrusion granulator, for example, a pre-extrusion granulator, a disk pelleter granulator, a ring die granulator, a basket granulator, an oscillating granulator, and a cylinder A type granulator etc. are mentioned.
  • the well-known additive which can be used for the pharmaceuticals which satisfy
  • the additive is not particularly limited, and examples include additives known as binders, lubricants, colorants, plasticizers, surfactants, sweeteners, flavoring agents, flavoring agents, and fragrances. , Binders and / or flavoring agents are preferred.
  • An additive may be used by 1 type and may be used as a 2 or more types of mixture.
  • binder examples include, but are not limited to, cellulose derivatives such as methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and hydroxypropylmethylcellulose phthalate, starches such as corn starch and wheat starch, polyvinylpyrrolidone (povidone), polyvinyl alcohol, Examples thereof include synthetic polymers such as acrylic acid polymers and natural polymers such as gum arabic and gelatin.
  • a corrigent For example, a citric acid, tartaric acid, aspartame, saccharin, a saccharin sodium, an erythritol, a xylitol, a mannitol, a stevia etc. are mentioned.
  • Flavoring agents also include additives known as sweeteners. Although it does not specifically limit as a flavoring agent and a fragrance
  • a flavoring agent and / or a flavoring agent is attached to the surface of the granule by a method described in Japanese Patent No. 3405342 for a granule containing isoleucine, leucine and valine.
  • the particle size of the granule to which the flavoring agent and / or the flavoring agent is attached is not particularly limited as long as the fluidized state can be easily maintained at the normal fluidized bed value, but is generally 100 to 2000 ⁇ m, preferably 200. It is about 1700 ⁇ m.
  • the fluidizing device for adhering the flavoring agent and / or the flavoring agent to the granule is not particularly limited.
  • the fluidizing drying device “Flow Dryer” manufactured by Freund Sangyo Co., Ltd. the fluid manufactured by Freund Sangyo Co., Ltd.
  • examples thereof include a layer granulation coating apparatus “Flow coater”, “Gratt GPCG” manufactured by Paulek, Inc., “Malmerizer” manufactured by Dalton Co., Ltd., and “Multiprocessor” manufactured by Kikusui Seisakusho Co., Ltd.
  • a gelling agent is mixed with a granule containing isoleucine, leucine and valine, preferably a granule to which a corrigent and / or a corrigent is attached.
  • a gelling agent it is preferable to add a gelling agent to a granule containing isoleucine, leucine and valine, preferably a granule to which a corrigent and / or a corrigent is attached, and mix.
  • Such a mixing method is not particularly limited as long as it can be mixed substantially uniformly.
  • a general container rotation type mixer eg, V type, double cone type, rotation swing type, etc.
  • container Examples thereof include a method using a mixer such as a fixed mixer (eg, ribbon type, conical screw type, etc.) or an airflow stirring type mixer.
  • a method may be used in which a prescribed amount of each preparation is put into a predetermined container and mixed by a packaging machine or the like.
  • the granule preparation of the present invention comprises a granule to which a gelling agent is added.
  • the granule is a granule prescribed by the Japanese Pharmacopoeia (refer to page 11 for the 17th revision of the Japanese Pharmacopoeia). .)
  • the particle size of the granule preparation is generally 100 to 2000 ⁇ m, preferably about 200 to 1700 ⁇ m.
  • the particle size means the average particle size of the particles, and can be measured by the general test method 3.04 “particle size measurement method” and the second method “sieving method” described in the 17th revision of the Japanese Pharmacopoeia. (Pages 95-97). In addition, it may be measured by the general test method 6.03 “Test method for particle size of the preparation” described in the 17th revision of the Japanese Pharmacopoeia (page 135).
  • the granule preparation of the present invention can be a granule preparation obtained by the method for producing a granule preparation of the present invention.
  • the granule preparation of the present invention has improved feelings of taking such as a bitterness derived from amino acids and a mouthfeel of granules.
  • a method for improving the ingestion feeling of a granule preparation containing isoleucine, leucine and valine as active ingredients by adding a gelling agent in powder form by adding a gelling agent in powder form.
  • the improvement in the feeling of taking include improvement of bitterness derived from amino acids and improvement of the mouthfeel of granule preparations.
  • Example 1 A granular preparation was prepared based on the formulation described in Table 1. To a mixture of L-isoleucine, L-leucine and L-valine, an aqueous solution of povidone (Collidon, 90F), polyvinyl alcohol (partially saponified product), tartaric acid and saccharin sodium hydrate was added, and stirred granulator The granules were granulated, sized and dried to obtain elementary granules. After spreading the fragrance
  • povidone Collidon, 90F
  • polyvinyl alcohol partially saponified product
  • the granules were granulated, sized and dried to obtain elementary granules. After spreading the fragrance
  • Comparative Example 1 A granular preparation was prepared based on the formulation described in Table 1. Elementary granules were obtained in the same manner as in Example 1. After coating with an aqueous solution of povidone (Kollidon, 90F) on the elementary granules, a fragrance was spread and sized to prepare a granule preparation.
  • povidone Kerdon, 90F
  • the granule preparation of Example 1 is a granule preparation that is superior in ease of swallowing, the difficulty of remaining granules, and the bitterness compared to the granule preparation of Comparative Example 1, which is a formulation of Leveract blended granules. I understood that.
  • Example 1 Using the granule preparations prepared in Example 1 and Comparative Example 1, the dissolution was evaluated by the dissolution test by the paddle method using the second dissolution test in the 17th revision of the Japanese Pharmacopoeia (pages 141-145 general test) Method 6.10 “Dissolution Test Method”). The results are shown in FIGS.
  • Example 1 The granule preparation of Example 1 was confirmed to have low elution at the initial stage (5 minutes value) with respect to the granule preparation of Comparative Example 1, but after 15 minutes, both preparations were almost 100% dissolved. It was confirmed to show sex. It was considered that the granule preparation of Example 1 also showed the same medicinal effect as the Levact mixed granule.
  • Examples 2-4 A granule formulation was prepared in the same manner as in Example 1 except that the content of polyethylene oxide (average molecular weight: 5 million) was 0.1%, 1%, or 2% with respect to the total amount of the granule formulation. Prepared.
  • Examples 5-7 A granule preparation was prepared in the same manner as in Example 1 except that polyethylene oxide having an average molecular weight of 500,000, 1 million or 2 million was used.
  • the granule preparation of the present invention has industrial applicability as a pharmaceutical granule preparation because it is considered to have improved dosing properties with respect to the rebact-blended granules of the current preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une préparation granulaire qui procure une sensation à l'ingestion améliorée et qui comprend de l'isoleucine, de la leucine et de la valine. La présente invention concerne une préparation granulaire comprenant de l'isoleucine, de la leucine et de la valine en tant que composant actif, la préparation granulaire contenant un agent gélifiant.
PCT/JP2018/005990 2017-02-21 2018-02-20 Préparation granulaire Ceased WO2018155435A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201880003639.1A CN109789120A (zh) 2017-02-21 2018-02-20 颗粒制剂
PH1/2019/500671A PH12019500671B1 (en) 2017-02-21 2018-02-20 Granular preparation
JP2019501340A JP7080215B2 (ja) 2017-02-21 2018-02-20 顆粒製剤
KR1020197007437A KR102555664B1 (ko) 2017-02-21 2018-02-20 과립 제제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-030368 2017-02-21
JP2017030368 2017-02-21

Publications (1)

Publication Number Publication Date
WO2018155435A1 true WO2018155435A1 (fr) 2018-08-30

Family

ID=63253165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/005990 Ceased WO2018155435A1 (fr) 2017-02-21 2018-02-20 Préparation granulaire

Country Status (6)

Country Link
JP (1) JP7080215B2 (fr)
KR (1) KR102555664B1 (fr)
CN (1) CN109789120A (fr)
PH (1) PH12019500671B1 (fr)
SG (1) SG10202109130WA (fr)
WO (1) WO2018155435A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526887A (ja) * 1997-12-20 2001-12-25 ジェネンコア インターナショナル インコーポレーテッド マトリクス顆粒
WO2009017193A1 (fr) * 2007-07-31 2009-02-05 Ajinomoto Co., Inc. Préparation granulaire médicinale contenant des acides aminés, très facile à prendre
JP2011093879A (ja) * 2009-10-02 2011-05-12 Ajinomoto Co Inc 分岐鎖アミノ酸を含有する顆粒、およびその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1040191A1 (zh) * 1998-07-31 2002-05-31 大塚制药株式会社 具有改良味道的药物组合物
JP3211824B1 (ja) * 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
JP3981134B2 (ja) * 2003-10-29 2007-09-26 塩野義製薬株式会社 不快味を改善した被覆製剤の製造方法
PE20141034A1 (es) * 2008-03-11 2014-09-10 Takeda Pharmaceutical Preparacion solida de desintegracion oral
JP5360368B2 (ja) * 2008-09-05 2013-12-04 味の素株式会社 服用感が改善された経口用アミノ酸製剤
JP2013014590A (ja) * 2012-08-02 2013-01-24 Otsuka Pharmaceut Co Ltd 消化管及び腎臓の萎縮抑制剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526887A (ja) * 1997-12-20 2001-12-25 ジェネンコア インターナショナル インコーポレーテッド マトリクス顆粒
WO2009017193A1 (fr) * 2007-07-31 2009-02-05 Ajinomoto Co., Inc. Préparation granulaire médicinale contenant des acides aminés, très facile à prendre
JP2011093879A (ja) * 2009-10-02 2011-05-12 Ajinomoto Co Inc 分岐鎖アミノ酸を含有する顆粒、およびその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Hand book of Pharmaceutical Excipients", INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL, 2007, pages 835 - 837 *

Also Published As

Publication number Publication date
KR20190117469A (ko) 2019-10-16
CN109789120A (zh) 2019-05-21
JPWO2018155435A1 (ja) 2019-12-12
PH12019500671A1 (en) 2019-07-24
PH12019500671B1 (en) 2024-02-02
SG10202109130WA (en) 2021-09-29
KR102555664B1 (ko) 2023-07-18
JP7080215B2 (ja) 2022-06-03

Similar Documents

Publication Publication Date Title
WO2009142255A1 (fr) Poudre de cellulose ayant un excellent effet de prévention de la ségrégation et compositions de celle-ci
CN103610680B (zh) 一种头孢呋辛酯组合物及其制备方法
JP6998210B2 (ja) 易服用性固形製剤用粒子組成物及び該粒子組成物を含む易服用性固形製剤
SG184951A1 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
CN115803020A (zh) 含有苯磺酸米洛巴林的口腔崩解片剂
WO2012133658A1 (fr) Boisson en bouteille avec un bouchon contenant un supplément alimentaire et une bouteille remplie d'un milieu de dispersion pour le supplément alimentaire
JP2016174616A (ja) 崩壊性組成物及び易崩壊性圧縮成型物
EP2983650A1 (fr) Composition pharmaceutique par voie orale comprenant de la n-acétylcystéine à goût masqué
JP5582033B2 (ja) 分岐鎖アミノ酸含有経口製剤
JP5515943B2 (ja) 分岐鎖アミノ酸を含有する顆粒、およびその製造方法
JPWO2019202968A1 (ja) 易服用性顆粒剤及びその製造方法
JP5275815B2 (ja) リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
JP7080215B2 (ja) 顆粒製剤
JP6384068B2 (ja) アミノ酸含有顆粒及びその製造方法
JP6104038B2 (ja) 結晶セルロースの複合組成物
JP2008162955A (ja) バリン含有高密度顆粒剤
JPWO2014017507A1 (ja) 固形製剤
JP2013136537A (ja) 錠剤及びその製造方法
HK40003126A (en) Granular preparation
JP2005008640A (ja) 不快な味を有する成分の不快な味を抑制した組成物
JP2007008872A (ja) 造粒粒子の製造方法およびその造粒粒子、並びに固形製剤
ES2384577T3 (es) Formulaciones granulares revestidas
JP2008189634A (ja) 口腔内速崩錠の製造方法
JP2023160929A (ja) 高分散性デキストリン粉末
JP6051059B2 (ja) エトドラク含有粒子及びエトドラク含有固形製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18756731

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20197007437

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019501340

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18756731

Country of ref document: EP

Kind code of ref document: A1